A result never seen before
In August, news that the first personalized mRNA cancer vaccine had succeeded in a late-stage trial thrilled oncologists and the public alike, even before its makers disclosed how well it worked. Now the figure is out: patients who received the vaccine with Keytruda had a 42% lower risk of their cancer returning after surgery or of dying than those who got Keytruda alone.
This new vaccine is something that we’ve never really seen before in terms of the efficacy that it has demonstrated and the way that it works.
Dr. Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center in the US. Merck and Moderna released the data early on Thursday, after reports that it had been published online and then taken down, ahead of its formal presentation in Madrid on Saturday.
















